The ASCO Post

🔬 #ASCOAI: AI and digital pathology continue to advance #precisiononcology. A new model predicted methylation-defined CNS tumor subtypes from routine H&E slides, helping narrow differential diagnoses and guide molecular testing. Explore the findings 👉 ascoai.org/articles/2026/…

🚨 #FDAApproval: The @US_FDA has granted approval for gedatolisib (Revtorpyk) + fulvestrant ± palbociclib for adults with HR+/HER2− metastatic #breastcancer without a PIK3CA mutation after endocrine therapy. Approval based on the VIKTORIA-1 trial. 🔗 ascopost.com/news/july-2026…

5️⃣-year follow-up from JCOG1008 confirms weekly cisplatin chemoradiotherapy remains noninferior to every-3-week cisplatin for overall survival in postoperative, high-risk locally advanced #HNSCC. 🔹 Makoto Tahara, MD, PhD | @JCO_ASCO 🔗 ascopost.com/news/july-2026…

🚨 #FDAApproval: The @US_FDA granted traditional approval to selpercatinib (Retevmo) for adults and children ≥2 years with locally advanced or metastatic RET fusion–positive solid tumors. Approval based on the LIBRETTO-001 and LIBRETTO-121 trials. 🔗 ascopost.com/news/july-2026…

✔️ First-line combination of disitamab vedotin, tislelizumab & S-1 showed high activity in HER2-overexpressing advanced gastric/GEJ cancer: ➡️ The Chinese phase 2️⃣ trial reported an 89.5% ORR and median OS of 31.9 months ▪️ Lian Liu, MD, PhD | @JCO_ASCO ascopost.com/news/july-2026…

🆕 preclinical findings point to a biomarker-driven strategy for resistant #melanoma High BCL2 expression predicted response to BCL2 inhibition + BRAF/MEK therapy, while high MCL1 predicted resistance. 🔸Vashisht Gopal Yennu Nanda, PhD | @NatureComms 🔗 ascopost.com/news/july-2026…

🖥️ #ASCOAI: Responsible #AI starts with responsible governance @TJCommission has launched the Responsible Use of AI in Healthcare certification, recognizing health systems with robust AI oversight, monitoring, transparency, and patient safety practices. 🔗 ascoai.org/articles/2026/…

💊 An all-oral regimen of revumenib + decitabine/cedazuridine + venetoclax showed activity in relapsed/refractory #AML. 🩸 The phase I/II SAVE trial reported a 71% composite CR rate with durable remissions. 🔹 Ghayas C. Issa, MD, MS | @JCO_ASCO 🔗 ascopost.com/news/july-2026…

⏰ Treatment delays matter in early-onset #colorectalcancer. A study of >112,000 patients found waiting >6 weeks after diagnosis for treatment was independently associated with worse OS in EOCRC (HR = 1.35). 🔸 Alex C. Kim, MD, PhD | @JAMAOnc 🔗 ascopost.com/news/july-2026…

🩸Inotuzumab ozogamicin induced measurable residual disease negativity in 70% of adults with B-cell acute lymphoblastic leukemia, deepening remissions. ➡️ Median OS reached 61 months, with an RFS of 40 months 🔹Elias Jabbour, MD | @BloodCancerJnl 🔗 ascopost.com/news/july-2026…

🎯 Precision testing can open new treatment options in #cholangiocarcinoma Phase II eNRGy trial: zenocutuzumab achieved a 36.8% ORR and 57.9% CBR in NRG1+ disease. ▪️ Supported recent #FDA approval. ▪️ James M. Cleary, MD, PhD | @JCO_ASCO 🔗 ascopost.com/news/july-2026…

How is #AI transforming #oncology this week? 🔹 FDA-cleared clinical AI raises questions 🔹 Quantum-inspired AI uncovers #neuroblastoma predictors 🔹 AI platform supports #cancer symptom management 🎥 Watch this week's #ASCOAI News Brief: ascoai.org/videos/weekly-…

🚹 Men may be more likely to receive later-stage #cancer diagnoses than women. An analysis of 2.4 million U.S. cancer cases found men had higher odds of a regional and/or distant-stage diagnosis across 20 solid tumors. 🔸 Beth Maclin, PhD, MPH 🔗 ascopost.com/news/july-2026…

🏳️‍🌈 #Cancerscreening disparities persist among sexual orientation and gender minority groups. 🆕 research found transgender individuals were 42% less likely to receive #cervicalcancer & 76% less likely to receive #breastcancer screening. ▫️ @timpawlik 🔗 ascopost.com/news/july-2026…

🧠 #ASCOAI: Can #AI unlock insights even from small datasets? A quantum mechanics–inspired AI framework modeled noisy, high-dimensional multiomic data and identified prognostic markers for neuroblastoma that may also represent future drug targets. 🔗 ascoai.org/articles/2026/…

🔟-year data support the long-term durability of CD19-directed #CARTcell therapy in lymphoma: 🔹 31.6% of patients achieved long-term remission, with no relapses beyond 5.4 years 🔹 Marco Ruella, MD & Stephen J. Schuster, MD | @NEJM | #Lymsm Learn more ➡️ ascopost.com/news/july-2026…

🚨 #FDAApproval: Pembrolizumab (Keytruda), with or without Keytruda Qlex, plus enfortumab vedotin (Padcev) is now approved as neoadjuvant/adjuvant therapy for muscle-invasive #BladderCancer Approval based on phase III KEYNOTE-B15/EV-304 trial. 🔗 ascopost.com/news/july-2026…

🚨 #FDAApproval: The @US_FDA approved subcutaneous isatuximab-irfc (Sarclisa Escena) in combo regimen indications for patients with newly diagnosed and relapsed/refractory #MultipleMyeloma. Approval supported by IRAKLIA, IZALCO, and IsaSocut studies. 🔗 ascopost.com/news/july-2026…

🖥️ #ASCOAI: What does @US_FDA clearance mean for clinical #AI? A closer look at the clearance for the UpDoc platform for personalized care delivery highlights an important distinction between an LLM interface and a clinical decision maker. Learn more: ascoai.org/articles/2026/…

🔬AI-powered analysis of routine pathology slides may help personalize immunotherapy for patients with rare cancers by identifying tumor microenvironment changes associated with improved outcomes. 🔸 @ANaingMD of @UTMDAnderson | @jitcancer Learn more ➡️ ascopost.com/news/july-2026…